{"anticipatedPostingDate":"2011-04","denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"The number of patients on Bortezomib that have maintained event-free survival, compared to the patients on observation was not analyzed due to low attrition rates.\n\nEvent-free survival is a measure of the proportion of people who remain free of a particular complication of disease (called an event) after treatment that is designed to prevent or delay that particular complication.","groups":[{"description":"Bortezomib will be administered as 12 monthly courses of 1.0 mg/m2 on days 1, 4, 8, and 11 and repeated every 28 days, followed by cycles administered every other month in year 2, and then every 3 months in year 3","id":"OG000","title":"Treatment Arm"},{"description":"Patients will be observed for progress over the course of three years.","id":"OG001","title":"Observation Arm"}],"reportingStatus":"POSTED","timeFrame":"three years","title":"Effect of Maintenance Therapy With Bortezomib on the Length of Remission in Participants Currently Receiving Maintenance Therapy as Part of Total Therapy 2","type":"PRIMARY"}